The estimated Net Worth of Alastair Stuart Mcewan is at least $1.01 Million dollars as of 12 June 2009. Alastair Mcewan owns over 46,704 units of Cortexyme Inc stock worth over $15,875 and over the last 20 years Alastair sold CRTX stock worth over $992,433.
Alastair has made over 5 trades of the Cortexyme Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Alastair sold 8,141 units of CRTX stock worth $73,269 on 19 June 2009.
The largest trade Alastair's ever made was exercising 119,041 units of Cortexyme Inc stock on 18 May 2009 worth over $51,188. On average, Alastair trades about 18,314 units every 2 days since 2004. As of 12 June 2009 Alastair still owns at least 8,141 units of Cortexyme Inc stock.
You can see the complete history of Alastair Mcewan stock trades at the bottom of the page.
Alastair's mailing address filed with the SEC is C/O CORNERSTONE THERAPEUTICS INC., 2000 REGENCY PARKWAY SUITE 255, CARY, NC, 27518.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi und Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: